BMAC for Osteoarthritis
(BMAC Trial)
Trial Summary
What is the purpose of this trial?
The purpose of this study is to investigate the safety and effectiveness of bone marrow aspirate concentrate (BMAC) in patients with moderate to severe osteoarthritis of the knee. BMAC provides a rich source of mesenchymal stem cells (MSCs) and is a stem cell-based therapy that has been reported to preserve or improve the structure of joints. The Angel System is the device used in this study to concentrate bone marrow from the patient and is intended to separate a mixture of blood and bone marrow and collect plasma rich platelets preoperative to a surgical procedure. The goal of this study is to identify whether BMAC can be an effective and safe treatment for patients with osteoarthritis of the knee.
Research Team
Eligibility Criteria
This trial is for men and women aged 45-75 with moderate to severe knee osteoarthritis, who have persistent pain despite standard treatments like acetaminophen, NSAIDs, physical therapy, or injections. They should need a total knee arthroscopy as determined by their primary care provider or orthopedist.Inclusion Criteria
Treatment Details
Interventions
- Angel Concentrated Platelet Rich Plasma (cPRP) System (Device)
- Bone Marrow Aspirate Concentrate (BMAC) (Stem Cell Therapy)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, San Diego
Lead Sponsor
Dr. Christopher Longhurst
University of California, San Diego
Chief Medical Officer since 2021
MD and MS in Medical Informatics from UC Davis
Patty Maysent
University of California, San Diego
Chief Executive Officer since 2016
MBA from Stanford University